Margarida Maia, PhD,  science writer—

Kaftrio (elexacaftor/tezacaftor/ivacaftor), branded as Trikafta in the U.S., may help clear the nasal passages and surrounding air-filled cavities, known as sinuses, in children and adolescents with cystic fibrosis (CF), according to a real-world study from France. In the MODUL-CF study (NCT04301856), which involved 391 children and adolescents…

Pregnancy does not negatively impact survival or lung function in women with cystic fibrosis (CF) and, in fact, may be associated with a lower risk of death, according to a U.S. study that compared CF women who had been pregnant with those who had never been pregnant. No significant…

Registration is now open for ResearchCon 2025, a free event the Cystic Fibrosis Foundation assembles each year for researchers, doctors, and patients to share and discuss the latest advances in research and clinical care in cystic fibrosis (CF). This virtual event, set online for May 6, provides…

Trikafta (elexacaftor/tezacaftor/ivacaftor) improves lung function and nutrition status in adults and adolescents with cystic fibrosis (CF), and appears to work particularly well in those with more severe lung disease, according to a real-world study from the U.S. Researchers also observed that Trikafta appears to work about as well…

In people with cystic fibrosis (CF) — particularly those with pancreatic insufficiency, which affects digestion — constipation typically led to longer hospital stays and higher healthcare costs, a study found. “Further work is needed to determine management strategies for constipation in hospitalized [people with CF], which may include early…

Despite often using a contraceptive at some point, unintended pregnancy remains fairly common among women with cystic fibrosis (CF) in the U.S, a survey study found. One in five women reported having an unplanned pregnancy, with the youngest being age 15, adding “to the growing evidence that suggests the…

Kaftrio, a combination of elexacaftor, tezacaftor, and ivacaftor that’s marketed as Trikafta in the U.S., may ease breathing and digestive symptoms in adults with cystic fibrosis (CF) who’ve had a lung transplant, a study from the Netherlands suggests. Researchers did observe a slight, but significant, increase in creatinine,…

Starting treatment with the CFTR modulator Orkambi (lumacaftor/ivacaftor) early in life may provide long-term benefits for children with cystic fibrosis (CF), yet lung function improvements may be temporary, according to a real-world study from Hungary. The study, “Body composition changes and clinical outcomes in pediatric cystic fibrosis…

After one year of treatment with Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor marketed as Trikafta in the U.S., the number of harmful bacteria growing in the lungs of people with cystic fibrosis (CF) declined significantly, a French study reports. “We observed a significant decrease in…

Dosing has begun in a Phase 2 clinical study testing ARCT-032, an experimental inhaled treatment Arcturus Therapeutics is developing for cystic fibrosis (CF) patients, including those who don’t benefit from CFTR modulators. The LunairCF study (NCT06747858) is recruiting adults with a diagnosis of CF who are…